Simplex Trading
ACRS icon

Simplex Trading’s Aclaris Therapeutics ACRS Stock Holding History

Simplex Trading’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Buy
20,200
+700
+4% +$3.12K ﹤0.01% 5463
2026
Q1 		$73.1K Buy
19,500
+18,500
+1,850% +$62.4K ﹤0.01% 5449
2025
Q4 		$3.01K Sell
1,000
-5,200
-84% -$13.1K ﹤0.01% 7683
2025
Q3 		$11K Buy
6,200
+2,500
+68% +$4.36K ﹤0.01% 7791
2025
Q2 		$5K Sell
3,700
-600
-14% -$812 ﹤0.01% 7694
2025
Q1 		$6K Sell
4,300
-19,500
-82% -$41.6K ﹤0.01% 7390
2024
Q4 		$59K Buy
23,800
+3,600
+18% +$8.96K ﹤0.01% 5697
2024
Q3 		$23K Buy
20,200
+7,600
+60% +$9.32K ﹤0.01% 6548
2024
Q2 		$13K Buy
12,600
+5,800
+85% +$6.82K ﹤0.01% 7220
2024
Q1 		$8K Sell
6,800
-28,400
-81% -$33.9K ﹤0.01% 7725
2023
Q4 		$36K Sell
35,200
-19,500
-36% -$59.5K ﹤0.01% 6386
2023
Q3 		$374K Buy
54,700
+42,200
+338% +$361K ﹤0.01% 3699
2023
Q2 		$129K Sell
12,500
-121,100
-91% -$1.1M ﹤0.01% 4774
2023
Q1 		$1.08M Buy
133,600
+133,300
+44,433% +$1.69M ﹤0.01% 2528
2022
Q4 		$4K Sell
300
-1,100
-79% -$17.7K ﹤0.01% 8157
2022
Q3 		$22K Sell
1,400
-8,300
-86% -$131K ﹤0.01% 7399
2022
Q2 		$135K Sell
9,700
-8,900
-48% -$125K ﹤0.01% 5148
2022
Q1 		$320K Buy
18,600
+15,700
+541% +$214K ﹤0.01% 4451
2021
Q4 		$42K Sell
2,900
-13,700
-83% -$208K ﹤0.01% 7465
2021
Q3 		$285K Hold
16,600
– – ﹤0.01% 4984
2021
Q2 		$291K Buy
16,600
+16,572
+59,186% +$376K ﹤0.01% 5026
2021
Q1 		$70K Buy
28
+3
+12% +$59 ﹤0.01% 6204
2020
Q4 		$16K Buy
+25
New +$105 ﹤0.01% 7104
2020
Q2 		– Sell
-60
Closed -$6K – 7497
2020
Q1 		$6K Sell
60
-12
-17% -$16 ﹤0.01% 6723
2019
Q4 		$13K Buy
+72
New +$119 ﹤0.01% 6223
2019
Q2 		– Sell
-3
Closed -$1K – 6999
2019
Q1 		$1K Buy
+3
New +$20 ﹤0.01% 6866
2018
Q3 		– Sell
-6
Closed -$11K – 7309
2018
Q2 		$11K Buy
+6
New +$111 ﹤0.01% 6267
2018
Q1 		– Sell
-20
Closed -$20K – 6019
2017
Q4 		$20K Buy
+20
New +$487 ﹤0.01% 3290

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Simplex Trading's ACRS Position: Q2 2026 in Review

Simplex Trading reduced its Aclaris Therapeutics (ACRS) stake by 51% in Q2 2026, selling an estimated $25.5K and leaving 5,499 shares worth $29.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6785.

Simplex Trading first reported a position in ACRS in Q4 2018 and has held it in 26 quarters since. The position peaked at $1.02M in Q1 2023. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Simplex Trading held 5,499 shares of Aclaris Therapeutics worth $29.1K as of Q2 2026.
  • Simplex Trading sold 5,717 Aclaris Therapeutics shares in Q2 2026, an estimated $25.5K.
  • Aclaris Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #6785 holding.
  • Simplex Trading first reported a position in Aclaris Therapeutics in Q4 2018 and has held it in 26 quarters since.
  • Simplex Trading's Aclaris Therapeutics position peaked at $1.02M in Q1 2023.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.